These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28025766)

  • 1. Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk.
    Tampieri A; Cipriano V; Mucci F; Rusconi AM; Lenzi T; Cenni P
    Intern Emerg Med; 2018 Jan; 13(1):87-93. PubMed ID: 28025766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study).
    Grönberg T; Hartikainen JE; Nuotio I; Biancari F; Ylitalo A; Airaksinen KE
    Am J Cardiol; 2016 Apr; 117(8):1294-8. PubMed ID: 26892448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.
    Femia G; Fetahovic T; Shetty P; Lee A
    Heart Lung Circ; 2018 Jul; 27(7):798-803. PubMed ID: 28802808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study.
    Airaksinen KE; Grönberg T; Nuotio I; Nikkinen M; Ylitalo A; Biancari F; Hartikainen JE
    J Am Coll Cardiol; 2013 Sep; 62(13):1187-92. PubMed ID: 23850908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strokes after cardioversion of atrial fibrillation--The FibStroke study.
    Palomäki A; Mustonen P; Hartikainen JE; Nuotio I; Kiviniemi T; Ylitalo A; Hartikainen P; Lehtola H; Luite R; Airaksinen KE
    Int J Cardiol; 2016 Jan; 203():269-73. PubMed ID: 26519683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).
    Sorino M; Colonna P; De Luca L; Carerj S; Oliva E; De Tommasi SM; Conti U; Iacopi F; D'Agostino C; D'Amato N; Pettinati G; Montericcio V; Cualbu A; De Luca I
    J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1034-42. PubMed ID: 18163016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre- and post-cardioversion transesophageal echocardiography for brief anticoagulation therapy with enoxaparin in atrial fibrillation patients: a prospective study with a 1-year follow-up.
    de Luca I; Sorino M; De Luca L; Colonna P; Del Salvatore B; Corlianò L
    Int J Cardiol; 2005 Jul; 102(3):447-54. PubMed ID: 16004890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anticoagulation and electrical cardioversion of chronic atrial fibrillation: proposal for an abbreviated protocol].
    Antonielli E; Pizzuti A; Gandolfo N; Sclavo M; Tanga M; Riva G; Leonardi G; Bassignana A; Di Leo M
    G Ital Cardiol; 1997 Aug; 27(8):803-10. PubMed ID: 9312508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study.
    Manning WJ; Silverman DI; Keighley CS; Oettgen P; Douglas PS
    J Am Coll Cardiol; 1995 May; 25(6):1354-61. PubMed ID: 7722133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
    Klein HH
    Dtsch Med Wochenschr; 2013 Jun; 138(24):1309-11. PubMed ID: 23737116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial fibrillation: prevalence and management in an acute general medical unit.
    Stewart FM; Singh Y; Persson S; Gamble GD; Braatvedt GD
    Aust N Z J Med; 1999 Feb; 29(1):51-8. PubMed ID: 10200813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study).
    Lip GY; Gitt AK; Le Heuzey JY; Bash LD; Morabito CJ; Bernhardt AA; Sisk CM; Chazelle F; Crijns HJ;
    Am J Cardiol; 2014 Feb; 113(3):480-4. PubMed ID: 24332698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial fibrillation patients with CHA2DS2-VASc >1 benefit from oral anticoagulation prior to cardioversion.
    Själander S; Svensson PJ; Friberg L
    Int J Cardiol; 2016 Jul; 215():360-3. PubMed ID: 27128562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
    Yadlapati A; Groh C; Passman R
    Am J Cardiol; 2014 Apr; 113(8):1362-3. PubMed ID: 24576547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new therapeutic strategy for electrical cardioversion of atrial fibrillation.
    de Luca I; Sorino M; Del Salvatore B; de Luca L
    Ital Heart J; 2001 Nov; 2(11):831-40. PubMed ID: 11770868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (The ACUTE Multicenter Study). Steering and Publications Committees of the ACUTE Study.
    Am J Cardiol; 1998 Apr; 81(7):877-83. PubMed ID: 9555778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.
    Camm AJ; Turpie AGG; Hess S; Amarenco P; Lambelet M; Haas S; van Eickels M; Kirchhof P;
    Europace; 2018 Jun; 20(6):e87-e95. PubMed ID: 29016755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.